Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
HOUSTON, May 31, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
